University of Dundee

Drug Discovery Unit

Short Code: 
DDU

DDU partners with Bukwang Pharmaceutical Company to tackle new drug treatment for Parkinson’s disease

The Drug Discovery Unit (DDU) has announced a multi-million-pound partnership with Korean-based Bukwang Pharmaceutical Company in a bid to develop a new drug treatment for Parkinson’s disease. This announcement builds upon existing drug discovery partnerships the DDU has with Takeda and GSK.

Parkinson’s disease is the second most common neurological disorder, after Alzheimer’s disease, affecting around two people in every 1000 across the population. There are around 6.1 million people worldwide and 120,000 people in the UK living with the condition.

mRNA cap methylation - a key player in cancer cell growth?

One of the most prevalent cancer-causing genes or “oncogenes” is called PI3KCA.  Damaging changes or “mutations” in this oncogene are found in many cancers including cancers of the breast, colon, brain, liver, stomach and lung.   Understanding how cancer-causing genes such as PIK3CA change the behaviour of our cells is key to developing new therapies for cancer patients. 

Natural products from the Amazon may help to treat neglected diseases

Researchers in the Wellcome Centre for Anti-Infectives Research (WCAIR) have been awarded £700,000 to investigate whether bacteria and other natural products found in the Amazon hold the key to developing new drugs for neglected tropical diseases. The team led by Professor Kevin Read will work with colleagues in Brazil to identify novel drug targets and develop new therapies for visceral leishmaniasis and Chagas’ disease.

Pages